Pharmacy Focus

FDA Announces Important New Safety Information Regarding Rituxan

The FDA recently announced that Genentech, Inc. has informed healthcare professionals nationwide of revisions to prescribing information for Rituxan (rituximab).

Healthcare professionals treating patients with Rituxan should consider progressive multifocal leukoencephalopathy (PML) in any patient presenting with new onset neurologic manifestations. Additionally, consultation with a neurologist, brain MRI and lumbar puncture should be considered as clinically indicated.

Read the entire 2008 MedWatch Safety Summary, including a link to the manufacturer's Dear Healthcare Professional Letter and updated prescribing information for Rituxan regarding the above issue, at: